FutureGen Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $42.8M
Latest Deal Amount
  • Investors
  • 5

FutureGen General Information

Description

Developer of biological R&D platform intended to discover antibody new drugs. The company develops antibody drugs to better treat cancer and tumor diseases, enabling patients to get better treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Science and Technology Complex
  • No. 7, Beinong Road, Science and Technology Park, Changping District
  • Beijing, 102206
  • China
+86 010 0000 0000

FutureGen Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FutureGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 01-Jan-2020 $42.8M 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A) 16-Apr-2018 000.00 000.00 Completed Pre-Clinical Trials
2. Early Stage VC 01-Jan-2016 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view FutureGen’s complete valuation and funding history, request access »

FutureGen Board Members (1)

Name Representing Role Since
Zhaoyu Jin Ph.D FutureGen Chairman Of the Board 000 0000
To view FutureGen’s complete board members history, request access »

FutureGen Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CICC Capital PE/Buyout Minority 000 0000 000000 0
DYEE Capital Venture Capital Minority 000 0000 000000 0
MSA Capital Venture Capital Minority 000 0000 000000 0
Sinopharm Capital Venture Capital Minority 000 0000 000000 0
Lilly Asia Ventures Venture Capital Minority 000 0000 000000 0
To view FutureGen’s complete investors history, request access »